There’s two ways of looking at this …
They wanted to give an opportunity for long term shareholders to participate at a low cost as this will be the last chance before the interim results are known.
If successful …
At that point it will no longer be shareholders funding any further .
It’s good to know …. In March 2024, the Company updated the market to report that 11 patients had
been dosed in the Phase 2a trial at that time
.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.3¢ |
Change
-0.008(3.13%) |
Mkt cap ! $113.1M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $307.4K | 1.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 885969 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 317712 | 11 |
View Market Depth
| Last trade - 10.50am 01/08/2025 (20 minute delay) ? |
| ATX (ASX) Chart |